<DOC>
	<DOCNO>NCT00515086</DOCNO>
	<brief_summary>This study define safety efficacy Everolimus ( RAD001 ) administer daily patient glioblastoma multiforme ( GBM )</brief_summary>
	<brief_title>Study Everolimus ( RAD001 ) Patients With Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>This multicenter , open label , randomize study RAD001 dose daily patient recurrent GBM . The study conduct 2 parallel group patient . Group 1 design study biological effect RAD001 patient schedule undergo salvage surgical resection , Group 2 enroll patient schedule surgery . Patients Group 1 randomly assign one three pre-surgery treatment group ( 0 , 5 10 mg/day RAD001 7 day ) . All patient Group 2 receive fix daily dose 10 mg/day oral RAD001 .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age 18 year age old Histologically confirm Glioblastoma Multiforme ( GBM ) Radiographic evidence disease progression Patients must evaluable contrast enhance tumor Availability paraffin block unstained pathology slide biomarker study Karnofsky Performance Status great equal 60 % Prior treatment Mammalian target rapamycin ( mTOR ) inhibitor History another malignancy within 3 year Cardiac pacemaker Ferromagnetic metal implant approve safe use Magnetic resonance imaging ( MRI ) scanner Claustrophobia Obesity Unstable systemic disease Elevated cholesterol triglyceride Radiation therapy cytotoxic chemotherapy &lt; =4 week prior study enrollment . Patient must recover toxic effect prior chemotherapy . Patients must enzyme induce anticonvulsant least 2 week study enrollment occur Need increase dose steroid . Patients stable taper dose steroid &gt; =7 day permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Glioblastoma Multiforme , GBM , RAD001 , RAD</keyword>
</DOC>